Evidence map›Paper›PMID 36851357›Full record

ArticleVaccines2023

Assessment of the Interferon-Lambda-3 Polymorphism in the Antibody Response to COVID-19 in Older Adults Seropositive for CMV.

Ariane Nardy, Camila Tussato Soares Camargo, Yasmim Faustina Castro de Oliveira, Fernanda Cristina da Silva, Millena Soares de Almeida, Fernanda Rodrigues Monteiro, Brenda Rodrigues Silva, Jônatas Bussador do Amaral, Danielle Bruna Leal Oliveira, Edison Luiz Durigon and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Ariane NardyFaculty of Pharmacy, Campus, Santo Amaro University, São Paulo 04829-300, Brazil.
Camila Tussato Soares CamargoFaculty of Pharmacy, Campus, Santo Amaro University, São Paulo 04829-300, Brazil.
Yasmim Faustina Castro de OliveiraFaculty of Pharmacy, Campus, Santo Amaro University, São Paulo 04829-300, Brazil.
Fernanda Cristina da SilvaFaculty of Pharmacy, Campus, Santo Amaro University, São Paulo 04829-300, Brazil.
Millena Soares de AlmeidaFaculty of Pharmacy, Campus, Santo Amaro University, São Paulo 04829-300, Brazil.
Fernanda Rodrigues MonteiroPost-Graduation Program in Health Sciences, Santo Amaro University (UNISA), São Paulo 04829-300, Brazil.
Brenda Rodrigues SilvaPost-Graduation Program in Health Sciences, Santo Amaro University (UNISA), São Paulo 04829-300, Brazil.ORCID 0000-0002-2370-2123
Jônatas Bussador do AmaralENT Research Laboratory, Department of Otorhinolaryngology-Head and Neck Surgery, Federal University of Sao Paulo (UNIFESP), São Paulo 04021-001, Brazil.ORCID 0000-0001-5819-0474
Danielle Bruna Leal OliveiraHospital Israelita Albert Einstein, São Paulo 05652-900, Brazil.ORCID 0000-0002-0534-0886
Edison Luiz DurigonLaboratory of Clinical and Molecular Virology, Department of Microbiology, Institute of Biomedical Science, University of São Paulo, São Paulo 05508-060, Brazil.ORCID 0000-0003-4898-6553
Guilherme Pereira ScagionLaboratory of Clinical and Molecular Virology, Department of Microbiology, Institute of Biomedical Science, University of São Paulo, São Paulo 05508-060, Brazil.
Vanessa Nascimento ChalupLaboratory of Clinical and Molecular Virology, Department of Microbiology, Institute of Biomedical Science, University of São Paulo, São Paulo 05508-060, Brazil.
Érika Donizetti CandidoLaboratory of Clinical and Molecular Virology, Department of Microbiology, Institute of Biomedical Science, University of São Paulo, São Paulo 05508-060, Brazil.ORCID 0000-0002-9132-569X
Andressa Simões AguiarLaboratory of Clinical and Molecular Virology, Department of Microbiology, Institute of Biomedical Science, University of São Paulo, São Paulo 05508-060, Brazil.
Neil Ferreira NovoPost-Graduation Program in Health Sciences, Santo Amaro University (UNISA), São Paulo 04829-300, Brazil.
Marina Tiemi ShioPost-Graduation Program in Health Sciences, Santo Amaro University (UNISA), São Paulo 04829-300, Brazil.
Carolina Nunes FrançaPost-Graduation Program in Health Sciences, Santo Amaro University (UNISA), São Paulo 04829-300, Brazil.
Luiz Henrique da Silva NaliPost-Graduation Program in Health Sciences, Santo Amaro University (UNISA), São Paulo 04829-300, Brazil.
André Luis Lacerda BachiPost-Graduation Program in Health Sciences, Santo Amaro University (UNISA), São Paulo 04829-300, Brazil.ORCID 0000-0001-8266-1416
Universidade de Santo Amaro · BRUniversidade de São Paulo · BRUniversidade Federal de São Paulo · BR

Funding

Fundação de Amparo à pesquisa do Estado de São Paulo 2016/20045-7 and 2020/06409-1 (ELD), no. 2019/14115-0 (ALLB), and no. 2020/11561-7 (AN).
6 · The paper itself

Abstract

backgroundHere, we investigated the impact of IFN-lambda-3 polymorphism on specific IgG responses for COVID-19 in older adults seropositive for CMV.

methodsBlood samples of 25 older adults of both sexes were obtained at three different times: during a micro-outbreak (MO) of SARS-CoV-2 in 2020; eight months after (CURE); and 30 days after the administration of the second dose of ChadOx-1 vaccine (VAC). The specific IgG for both SARS-CoV-2 and CMV antigens, neutralizing antibodies against SARS-CoV-2, and also the polymorphism profile for IFN-lambda-3 (rs12979860 C > T) were assessed.

resultsHigher levels of specific IgG for SARS-CoV-2 antigens were found in the MO and VAC than in the CURE time-point. Volunteers with specific neutralizing antibodies against SARS-CoV-2 showed better specific IgG responses for SARS-CoV-2 and lower specific IgG levels for CMV than volunteers without specific neutralizing antibodies. Significant negative correlations between the specific IgG levels for SARS-CoV-2 and CMV were found at the MO time-point, as well as in the group of individuals homozygous for allele 1 (C/C) in the MO time-point and heterozygotes (C/T) in the CURE time-point.

conclusionOur results suggested that both CMV seropositivity and the homozygosis for allele 1 (C/C) in IFN-lambda-3 gene can negatively impact the antibody response to COVID-19 infection and vaccination in older adults.

Indexed as

allelecytomegalovirusimmunoglobulinsneutralizing antibodyoutbreakSARS-CoV-2

Identifiers

PMID36851357
PMCPMC9963200
OpenAlexW4321372324

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.